NCT05408429: A trial that was reported late by Pfizer
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05408429 |
|---|---|
| Title | A Phase 3, Randomized, Partially Double-Blind Trial to Evaluate the Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine in Healthy Toddlers 12 Through 23 Months of Age With 2 Prior Infant Doses of Prevenar 13 |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 30, 2022 |
| Completion date | Dec. 28, 2022 |
| Required reporting date | Dec. 28, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Sept. 12, 2022 |
| Days late | None |